Home › Calculator › RDHL Dividend Calculator 2026
RDHL Dividend DRIP Calculator 2026
287.77% YieldHealthcareRedHill Biopharma Ltd. · NASDAQ
Price: $0.70 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When RDHL pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your RDHL snowball 📈
$10,000 in RDHL → $19037317496558392.00M in 10 years · $1,585,904,939,199,164,800,000.00/month
About RedHill Biopharma Ltd. (RDHL) — Dividend Analysis 2026
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Compare RDHL with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full RDHL DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open RDHL position with:
🌍 RDHL Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold RDHL.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 287.77% | 284.97% | $28,777 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 244.60% | 241.80% | $24,460 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 230.22% | 227.42% | $23,022 / yr |
| 🇬🇧 UK ISA | 0% | 287.77% | 284.97% | $28,777 / yr |
| 🇬🇧 UK Taxable | 8.75% | 262.59% | 259.79% | $26,259 / yr |
| 🇨🇦 TFSA | 0% | 287.77% | 284.97% | $28,777 / yr |
| 🇨🇦 CA Taxable | 25% | 215.83% | 213.03% | $21,583 / yr |
| 🇦🇺 Super (pension) | 15% | 244.60% | 241.80% | $24,460 / yr |
| 🇦🇺 AU Taxable | 30% | 201.44% | 198.64% | $20,144 / yr |
| 🇩🇪 DE Taxable | 26.375% | 211.87% | 209.07% | $21,187 / yr |
| 🇫🇷 FR Taxable | 30% | 201.44% | 198.64% | $20,144 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 RDHL Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 RDHL Dividend Payment Schedule
RDHL pays quarterly — 4 times per year. Next ex-div: TBD.
📊 RDHL vs Healthcare Benchmarks
How RDHL compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for RDHL sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ RDHL Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-07-10 | 14,130,000 | $0.00 | $1.4K | ||
| M-Exempt | 2026-07-10 | 28,150,000 | — | — | ||
| Sale | 2026-04-06 | 15,740,000 | $0.00 | $1.6K | ||
| M-Exempt | 2026-04-06 | 30,780,000 | — | — | ||
| Other | 2026-03-18 | 36,440,000 | — | — | ||
| Other | 2026-03-18 | 180,000 | — | — | ||
| Other | 2026-03-18 | 73,640,000 | — | — | ||
| Other | 2026-03-18 | 840,000 | — | — | ||
| Other | 2026-03-18 | 25,830,000 | — | — | ||
| Other | 2026-03-18 | 250,000 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the RDHL dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
RedHill Biopharma Ltd. (RDHL) is currently trading at $0.70, trading near its 52-week low. The current dividend yield is 287.77% based on an annual payout of $2.00 per share.
RDHL (RedHill Biopharma Ltd.) — 287.77% Dividend Yield Analysis
RedHill Biopharma Ltd. (RDHL) is a healthcare stock currently trading at $0.69 with a dividend yield of 287.77%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (287.77%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.